First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 4,564,207 | $137,702,125 | +137% | 4.46% |
| 2. | Citadel Investment Group Ken Griffin | 3,480,062 | $104,993,471 | +61% | 0.02% |
| 3. | OrbiMed Advisors Samuel Isaly | 2,540,136 | $76,635,903 | -10% | 1.83% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 2,092,011 | $63,115,972 | +56% | 0.14% |
| 5. | 61,466,000 | $60,635,376 | -23% | 1.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.86 | 15,000 | $477,900.00 | 50,219 | 2025-05-01 | Filing | |
| $36.23 | 2,500 | $90,583.00 | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | $90,495.75 | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.37 | 680 | $19,291.60 | 56,660 | 2025-04-16 | Filing | |
| $28.36 | 3,016 | $85,533.76 | 11,199 | 2025-04-16 | Filing | |
| $28.40 | 3,928 | $111,555.20 | 31,926 | 2025-04-16 | Filing | |
| $32.32 | 140 | $4,524.80 | 180,980 | 2025-03-11 | Filing | |
| $32.35 | 1,207 | $39,046.45 | 56,245 | 2025-02-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 23,613,585 | $712,421,869 | 0.05% | |
| 2. | 16,383,934 | $494,303,288 | 0.01% | |
| 3. | 12,361,994 | $372,961,359 | 0.06% | |
| 4. | 11,264,442 | $339,848,216 | 0.01% | |
| 5. | 8,416,421 | $253,923,422 | 0.05% |
News See All
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire Glenn Russell Dubin's 10 Stock Picks with Huge Upside Potential
Glenn Russell Dubin is one of the industry's most experienced hedge fund managers, best known as the co-founder of Highbridge Capital Management, a multi-strategy investment business he founded with Henry...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Ionis First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Ionis Pharmaceuticals, Inc.'s Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
Billionaire Hedge Funds
